Walleye Capital
CLVS

Walleye Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Walleye Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-28,000
Closed -$178K – 1078
2020
Q1 		$178K Sell
28,000
-76,000
-73% -$610K 0.04% 468
2019
Q4 		$1.08M Sell
104,000
-28,500
-22% -$207K 0.07% 386
2019
Q3 		$521K Buy
132,500
+120,300
+986% +$973K 0.03% 732
2019
Q2 		$181K Buy
+12,200
New +$220K 0.02% 1008

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Walleye Capital's CLVS Position: Q4 2019 in Review

Walleye Capital sold out of Clovis Oncology, Inc. (CLVS) in Q4 2019, closing a stake of 51,238 shares — an estimated $373K sold.

Walleye Capital first reported a position in CLVS in Q2 2019 and held it in 2 quarters. The position peaked at $324K in Q2 2019. 147 funds tracked by Wall St. Rank hold CLVS as of Q4 2019.

  • Walleye Capital reported no remaining Clovis Oncology, Inc. position as of Q4 2019 after selling out during the quarter.
  • Walleye Capital sold 51,238 Clovis Oncology, Inc. shares in Q4 2019, an estimated $373K.
  • Walleye Capital first reported a position in Clovis Oncology, Inc. in Q2 2019 and held it in 2 quarters.
  • Walleye Capital's Clovis Oncology, Inc. position peaked at $324K in Q2 2019.
  • 147 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2019.

Based on Walleye Capital's 13F filing for Q4 2019, filed 14 Feb 2020.